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Abstract—Synthetic C-reactive protein (CRP) rescues mice from lethal endotoxin shock or bacte-
rial infection by suppressing tumor necrosis factor (TNF-α), but in turn, enhances Kupffer cell
phagocytic activity. We herein assessed the inﬂuence of CRP in human peripheral blood mononu-
clear cells (PBMCs). When human PBMCs were stimulated in vitro with penicillin-treated Strept-
ococcus pyogenes, bacterial DNA motifs and lipopolysaccharide with or without synthetic CRP,
CRP suppressed the production of TNF-α and IL-12, but not that of IFN-γ. This was also the case
for the in vitro Shwartzman reaction induced in PBMCs. CRP also decreased high-mobility group
box 1 production from macrophages, which is crucial in the later phase of endotoxin/septic shock.
However, CRP upregulated the perforin expression by CD56+ NK cells and increased their
antitumor cytotoxicity. CRP may thus be a potent immunomodulatory factor in the human immune
system, suggesting its therapeutic potential for use against human septic shock.
KEY WORDS: inﬂammation; C-reactive protein; tumor necrosis factor-α; high-mobility group box 1; human
PBMCs.
INTRODUCTION
C-reactive protein (CRP), named for its capacity to
precipitate the somatic C-polysaccharide of Streptococ-
cus pneumoniae, is an acute-phase protein produced by
hepatocytes in response to infections and tissue damage
[1, 2]. Several reports suggested that CRP as well as
functional CRP peptides have positive and regulatory
effect on the innate immunity against infections and tumors
[3, 4], however, the role of CRP on innate immunity has
not been fully elucidated. We have recently reported that
pretreatment with synthetic CRP prevents mice from
developing either lethal endotoxemia or E. coli infection
by suppressing TNF production, while it simultaneously
enhances the phagocytic activity of Kupffer cells. Even if it
is used after the onset of E. coli infection, synthetic CRP
decreases the mouse mortality [5]. It also prevents mice
from developing either generalized Shwartzman reaction
or multi-organ failure induced by consecutive injection of
IL-12 and LPS into mice by inhibiting TNF production [5].
Shwartzman reaction-like response was also reproduced by
human PBMCs in vitro [6].
Innate immune cells, macrophages, produce proin-
ﬂammatory cytokines, such as TNF and IL-12, after
activation with LPS via toll-like receptor (TLR)-4 or
hypomethylated common bacterial DNA motifs (CpG-
ODN) via toll-like receptor-9 [7]. IL-12 produced by
macrophages/Kupffer cells stimulates natural killer (NK)
cells and NKT cells to produce another proinﬂammatory
cytokine, IFN-γ, which in turn activates macrophages/
Kupffer cells to increase their phagocytosis and cytokine
production in a positive feedback loop [7]. These
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reactions are indispensable for effective suppression of the
growth and dissemination of invading bacteria. Bacterial
activation may also increase the function of innate immune
cells to survey and suppress tumor growth. Human TCR(−)
mononuclear cells with NK cell markers CD56 or CD57
are known to correspond to mouse NK cells having the
antitumor cytotoxicity [8, 9]. Human NK cells express
either CD56 or CD57 and CD56+ NK cells usually show
more potent antitumor cytotoxicity than CD57+ NK cells
[10]. These CD56+NK cells and CD56+T (human NKT)
cells play a primary role in the elimination of tumor cells
when activated with cytokines, IL-2 and IL-12 or bacterial
stimulation [8, 11, 12, 9]. On the other hand, uncontrolled
activation of macrophages/Kupffer cells, NK cells and
NKTcells in mice causes vascular endothelial cell damage
and exacerbates multi-organ dysfunction syndrome
(MODS) induced by LPS [9, 13–15].
High mobility group box 1 (HMGB1) is usually
located in the cytosol and nucleus of macrophages, but is
secreted from macrophages in response to bacterial
infections and acts as a proinﬂammatory cytokine.
HMGB1 is now known to be a crucial late mediator of
septic shock and MODS [16–18].
In the present study, we investigated how CRP
affects the functions of macrophages and NK cells in
human PBMCs after stimulation with a streptococcus
reagent (OK-432), CpG-ODN, LPS or during in vitro
Shwartzman-like reaction. Consistent with our recent
report using a mouse model [5], we observed that
CRP decreases the production of proinﬂammatory
cytokines and HMGB1 from human PBMCs stimulat-
ed with these reagents, without decreasing the IFN-γ
production. In addition, CRP increased the antitumor
activity of NK cells.
MATERIALS AND METHODS
Peripheral Blood Samples
Heparinized peripheral blood samples were
obtained several times from eight healthy adult volun-
teers. We obtained informed consent from all volunteers
and also received approval from the ethics committee of
our medical school.
Reagents
Synthetic CRP peptide (174–185) was purchased
from BACHEM (King of Prussia, PA, USA). Penicillin-
treated Streptococcus pyogenes (OK-432) was purchased
from Chugai (Tokyo, Japan). Human CpG-ODN
(HC4032: TCGTCGTTTTGTCGTTTTGTCGTT) was
purchased from Hycult Biotechnology (Uden, Nether-
lands). LPS (Escherichia coli 0111:B4) was purchased
from Sigma Chemical Co. (St. Louis, MO, USA).
Recombinant human IL-12 (p70) was purchased from
Strathmann Biotec (Hamburg, Germany).
Isolation of PBMCs and Separation of Adherent
Macrophages
Blood samples were obtained and PBMCs were
isolated using a lymphocyte separation medium (MP
Biomedicals., LLC-Cappel Prod, Ohio, USA) and
gradient centrifugation. The gravity of the lymphocyte
separation medium is 1.077–1.080 g/ml at 20 °C.
PBMCs were suspended at 1×106 cells/ml in RPMI
1640 containing 20 % human serum and were cultured
on plastic plates for 1 h in 5 % CO2 at 37 °C to separate
the macrophages and lymphocytes. Non-adherent
lymphocytes were obtained by gentle pipetting, and
subsequently, and non-adherent lymphocytes (1×106
cells/ml) and the remaining plastic adherent cells
(mainly monocytes/macrophages, up to 20 % of
PBMC) were separately stimulated by bacterial
reagents for the indicated periods.
Co-incubation of PBMCs or Adherent Macrophages
with Synthetic CRP and Bacterial Reagents
(Including In Vitro Shwartzman Reaction)
Total PBMCs (1 × 106 cells/ml), adherent
macrophages (usually up to 20 % of PBMCs) or non-
adherent lymphocytes (1×106 cells/ml) were suspended
in RPMI 1640 containing 20 % human serum and were
then cultured on 48-well ﬂat-bottom plates in 5 % CO2
at 37 °C with or without 200 μg/ml of synthetic CRP
peptide. An aliquot of 0.5 μg/ml OK-432, 1.5 mg/ml
CpG-ODN, 10 ng/ml LPS or PBS (as control) was
added to the culture medium just after CRP
administration, and the cells were cultured for 48 h. An
in vitro Shwartzman reaction was also induced in the
blood cells [6]. PBMCs were cultured with 2 ng/ml of
IL-12 (p70) for 24 h with or without CRP. A sample of
10 ng/ml of LPS was added to the culture medium and
the cells were cultured for an additional 24 h. To
examine the cytokine productions from macrophages,
adherent macrophages were cultured with IL-12 with or
without CRP for 24 h and the macrophages were
cultured with LPS for additional 24 h. Four to eight
independent experiments were performed.
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Assays for TNF, IFN-γ, IL-6, IL-12 (p40 and p70),
IL-10 and HMGB1 Levels
The TNF, IFN-γ, IL-6, IL-12 and IL-10 levels in
the culture supernatants were measured using cytokine-
speciﬁc ELISA kits (OptEIATM, PharMingen, San
Diego, USA). The HMGB1 level in the culture super-
natants was measured using a commercially available
ELISA (Shino-Test Corporation; distributed by IBL
Hamburg) according to the manufacturer’s directions.
Flow Cytometric Analysis (Including Intracellular
Staining for Perforin) of PBMCs
A three-color immunoﬂuorescence test was per-
formed. PBMCs were stained with ﬂuorescein isothio-
cyanate (FITC)-conjugated anti-human αβ TCR Ab,
phycoerythrin(PE)-conjugated anti-CD57 Ab and PC5-
conjugated anti-CD56 Ab. A commercially available kit
(BD Cytoﬁx/Cytoperm solution, BD Pharmingen) and a
FITC-conjugated anti-human perforin Ab (Ancell cor-
poration, Bay port, MN) or isotype-matched Ab (anti-
mouse IgG2bκ) were used for intracellular staining of
perforin. The cells were stained with PE-conjugated anti-
CD56 Ab and PC5-conjugated anti-αβ TCR Ab,
followed by staining with anti-perforin Ab or isotype
Ab. The cells were analyzed using the EPICS XL and
FC500 devices (Beckman Coulter, Miami, FL).
Cytotoxicity Assays Against Tumor Cells
The calcein-AM-based Terascan assay was per-
formed to estimate the effect of synthetic CRP on the
cytotoxicity of PBMCs stimulated by bacterial
ligands. For the cytotoxicity assays against tumor
cells, NK-sensitive K562 cells (a MHC class-I
negative tumor cell line) and NK-resistant Raji cells
(a MHC class-I negative tumor cell line) were used as
target cells. The target cells were labeled with 10 μg/
ml calcein-AM (Kohjin Bio, Saitama, Japan) for each
cytotoxicity assay. The stimulated PBMCs were used
as effector cells. The labeled target tumor cells were
co-cultured with effector cells at 37 °C in a fully
humidiﬁed 5 % CO2 atmosphere in 96-well plates for
4 h. For the calcein-AM-based Terascan assay, the
plate was placed on a microscope stage of the
Terascan instrument (MinervaTech, Tokyo, Japan),
which serially measured the ﬂuorescence emitted by
intact target cells during co-culture of the target and
effector cells.
Cell Sorting and Culture of PBMCs
PBMCs were stained with PE-conjugated anti-
CD56Ab, anti-CD57 Ab or PC5-conjugated anti-αβ
TCR Ab. The cells were then labeled with anti-PE
microbeads or anti-PC5 microbeads. CD56, CD57 or αβ
TCR-positive cells were depleted by magnetic-activated
cell sorting system (MACS; Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany). The CD56+, CD57+ or
αβ TCR+ cell-depleted PBMCs were suspended at
1×106 cells/ml in RPMI 1640 containing 20 % human
serum and then were cultured with stimulation by OK-
432, CpG-ODN or LPS with or without synthetic CRP
peptide on 48-well ﬂat-bottom plates in 5 % CO2 at
37 °C for 48 h. After the culture, they were used for
cytotoxic assays.
Statistical Analysis
Statistical analyses were performed using the Stat-
View 4.02 J software package (Abacus Concepts,
Berkley, CA). Statistical evaluations were made using a
one-way analysis of variance [17] or a two-way
ANOVA, followed by the Fisher PLSD test. The data
are presented as the means ± standard error (SE). p<0.05
was considered to be statistically signiﬁcant.
RESULTS
The Effect of CRP on the Production of Proinﬂammatory
Cytokines from PBMCs or Adherent Macrophages
Stimulated with Bacterial Reagents
PBMCs or adherent macrophages were cultured
with OK-432, CpG-ODN or LPS for 48 h with or
without CRP. The culture supernatants were collected at
the indicated time points. Synthetic CRP treatment
signiﬁcantly suppressed the production of TNF and IL-
12 but not IFN-γ from the pathogen-stimulated PBMCs
(Fig. 1). CRP decreased TNF and IL-12 production from
adherent macrophages stimulated with each bacterial
reagent (Fig. 2). The production of IL-6 and IL-10 from
either PBMCs or adherent macrophages (except IL-6
from PBMCs) stimulated with bacterial reagents was
also decreased by CRP (Fig. 3). The productions of
cytokines from adherent macrophages were lower than
those from PBMCs, suggesting that direct contact with
lymphocytes and/or their cytokines including IFN-γ
may be needed for macrophages to produce sufﬁcient
cytokines. Non-adherent lymphocytes, including NK
783Suppression of Proinﬂammatory Cytokines by CRP
cells and T cells, stimulated with reagents did not
produce these cytokines, if any (data not shown). In
addition, CRP did not affect the weak proliferative
activities of PBMCs stimulated with bacterial
reagents, such as CpG-ODN or LPS for 48 h, as
demonstrated by [3H] thymidine uptake experiments
(up to 3,000 cpm). However, a side scatter analysis
of the ﬂow cytometry showed that many lymphocytes
(mainly CD56+ cells) exhibited the large blastic
morphology at 48 h after culture with bacterial
reagents (data not shown), thus indicating that they
were activated.
Synthetic CRPAugmented the Antitumor Cytotoxicity
of PBMCs Against Raji and K562 Cells After
Stimulation with Bacterial Reagents
We examined the effects of synthetic CRP on the
antitumor cytotoxicity of activated PBMCs. PBMCs
were cultured with OK-432, CpG-ODN or LPS, for 48 h
with or without synthetic CRP. Thereafter, the PBMCs
were collected, and their antitumor cytotoxicity against
Raji and K562 tumor cells was evaluated. The stimulat-
ed PBMCs showed potent cytotoxicity against both
tumor cell lines. Co-culture with synthetic CRP further
Fig. 1. Synthetic CRP modulates proinﬂammatory cytokine production from bacterial reagent-stimulated PBMCs. PBMCs were cultured with bacterial
reagents with or without CRP for 48 h. The culture supernatants were collected at the indicated time points and were subjected to an ELISA for TNF, IL-12
(p40&p70) and IFN-γ. The data are presented as the means ± SE eight independent experiments. **p<0.01 vs CRP (+) group by two-way ANOVA.
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augmented the antitumor cytotoxicity of these PBMCs
against both K562 and Raji cells (Table 1). Depletion of
CD56+ cells but not of CD57+ cells or αβ T cells by
magnetic beads substantially decreased the cytotoxicity of
the PBMCs against both tumor cell lines (Table 2).
Therefore, CD56+ NK cells (including some CD56+ T
cells) are considered to be the main antitumor effectors,
although T cells may have some cytotoxic effects. When
CD56+ cells were puriﬁed from PBMCs cultured for 48 h
with each of the bacterial reagents and cytotoxic assays were
performed, they consistently exhibited strong cytotoxicity
against both K562 and Raji cells (data not shown).
Synthetic CRP Increased the Intracellular Perforin
in NK Cells After Bacterial Stimulation
To examine the mechanism underlying the ob-
served increase in the antitumor effector function of the
cells, we assessed the effects of synthetic CRP on the
phenotype and proportion of PBMCs stimulated with
OK-432, CpG-ODN, or LPS for 48 h. Co-culture with
synthetic CRP tended to increase the proportion of
CD56+ NK cells, although the difference was not
statistically signiﬁcant (Fig. 4). CRP signiﬁcantly
increased the proportions (in percent) of perforin-
expressing CD56+ NK cells and their perforin
intensities in the pathogen-stimulated PBMCs (Fig. 4).
In addition, synthetic CRP did not affect the weak
perforin expression of CD57+ NK cells (data not
shown). Therefore, the increased antitumor cytotoxicity
is considered to be attributable to the functional
enhancement of CD56+ NK cells.
Synthetic CRP Affects the Function of PBMCs
After In Vitro Shwartzman Reaction
We previously reported that PBMCs, cultured with
IL-12 (p70) for 24 h and with LPS for an additional
24 h, produced a much larger amount of TNF than
PBMCs without IL-12 priming (in vitro Shwartzman
reaction) [6]. CRP also decreased the production of TNF
and IL-12 (p40 and p70) but not IFN-γ from PBMCs
(mainly NK cells) or macrophages during in vitro
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Fig. 2. Synthetic CRP modulates proinﬂammatory cytokine production from adherent macrophages stimulated with bacterial reagents. Adherent
macrophages were cultured with bacterial reagents with or without CRP for 48 h. The culture supernatants were collected at the indicated time points
and were subjected to an ELISA for TNF and IL-12 (p40 and p70). The data are presented as the means ± SE from six independent experiments.
**p<0.01 vs CRP (+) group by two-way ANOVA.
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CRP Treatment Reduces HMGB1 Production
by PBMCs or Adherent Macrophages
HMGB1 was recently shown to be secreted by
macrophages, and is a late mediator of septic shock
and lethality induced by either LPS or CpG-ODN
[17]. Therefore, we next examined whether CRP
affects HMGB1 secretion. We observed that the
HMGB1 levels stimulated by the three reagents or
the in vitro Shwartzman reaction were substantially
inhibited by CRP treatment in both PBMCs (Fig. 6a)
and macrophages (Fig. 6b).
DISCUSSION
TLR family is a phylogenetically conserved family
of proteins that mediate innate immune reactions and are
essential for microbial recognition [19]. LPS (a gram-
negative bacterial component) and CpG-ODN (unme-
thylated common bacterial DNA of a speciﬁc sequence)
engage TLR4 and TLR9, respectively. In addition, TLR2
can recognize lipoproteins/lipopeptides of gram-positive
bacteria such as S. pyogenes. Macrophages recognize
these bacterial components through TLRs and produce
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Fig. 3. Synthetic CRP modulates cytokine productions from bacterial reagent-stimulated PBMCs (a) and adherent macrophages (b). PBMCs or
adherent macrophages were cultured with bacterial reagents with or without CRP for 48 h. The culture supernatants were collected at the indicated
time points and were subjected to an ELISA for IL-6 and IL-10. The data are presented as the means ± SE from six independent experiments.
**p<0.01, *p<0.05 vs CRP (+) group by two-way ANOVA.
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Table 1. The Effects of Synthetic CRP on the Cytotoxic Activities of PBMCs Stimulated with Bacterial Reagents
% Cytotoxicity at different E/T ratios
Target Treatment of PBMCs 40:1 20:1












50:81:8  **LPS + CRP












LPS + CRP 29.8±2.6
Mean ± SE vs other groups
**p<0.01; *p<0.05
Table 2. The Cytotoxic Activities of NK Cells or T Cell-depleted PBMCs
% Cytotoxicity at different E/T ratios
Target 40:1 20:1
Raji Control (PBS) Total PBMCs 30.7±4.2 21.4±1.3
OK432 Total PBMCs 58:61:9
22:80:6  **
24:50:4
17:60:9  **CD56 (−) PBMCs
CD57 (−) PBMCs 59.8±1.3 38.3±1.1
T cell (−) PBMCs 56.1±1.6 26.5±0.6
CpG Total PBMCs 44:42:0
23:40:2  **
23.1±1.7
CD56 (−) PBMCs 17.4±1.7
CD57 (−) PBMCs 39.4±0.9 31.8±0.6
T cell (−) PBMCs 44.1±2.5 23.1±0.1
LPS Total PBMCs 62:01:3
30:90:8  **
41:00:5
28:80:5  **CD56 (−) PBMCs
CD57 (−) PBMCs 49.2±1.3 39.2±1.2
T cell (−) PBMCs 56.2±0.4 37.4±1.9







CD57 (−) PBMCs 37.7±1.1 31.3±0.6
T cell (−) PBMCs 37.7±1.0 26.5±0.6
CpG Total PBMCs 30:82:4
20:91:4  *
18.0±1.2
CD56 (−) PBMCs 16.4±0.8
CD57 (−) PBMCs 29.8±1.2 26.9±0.7
T cell (−) PBMCs 28.4±1.2 17.1±0.9
LPS Total PBMCs 32:40:9
18:70:9  *
19.0±1.5
CD56 (−) PBMCs 18.3±0.6
CD57 (−) PBMCs 30.5±1.1 28.0±1.1
T cell (−) PBMCs 31.1±0.6 19.6±0.1
Mean ± SE vs other groups
**p<0.01; *p<0.05
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activate NK cells and NKT cells to produce IFN-γ and
acquire antitumor activity [7]. Of particular interest,
although synthetic CRP reduced IL-12 and TNF pro-
duction from activated monocytes/macrophages which is
a potent IFN-γ inducer from NK/NKT cells, it did not
inhibit IFN-γ production from NK cells and T cells and
augment antitumor cytotoxicity of NK cells.
CRP is elevated in septic patients in response to
bacterial invasion, and peaks at 100∼200 mg/L approx-
imately 48 h after the onset of sepsis or exposure of
bacterial toxins [20, 21]. Native CRP is a pentraxin with
a molecular weight of 115 kDa [1, 2]. The synthetic
CRP peptide used in the current study is a fragment of
native CRP and homologous to amino acid residues
174–185 (Ile–Tyr–Leu–Gly–Gly–Pro–Phe–Ser–Pro–
Asn–Val–Leu). The molecular weight is 1.3 kDa, which
is about 100th of that of native CRP. The synthetic CRP
has been reported to have a biological activity which is
similar to that of native CRP [3, 4]. We demonstrated
that synthetic CRP generally suppressed the production
of the proinﬂammatory cytokines, TNF, and IL-12, from
human macrophages, whereas it did not affect the IFN-γ
production from NK cells and T cells. These results are
consistent with our recent report in which synthetic CRP
was found to decrease the serum TNF and IL-12 levels,
but not IFN-γ levels, after E. coli infection or endotoxin
shock in mice [5]. CRP may exert its effect via binding
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Fig. 4. Synthetic CRP increased the intracellular perforin in NK cells after bacterial stimulation. a The ﬂow cytometric proﬁle of CD56+ and CD57+
NK cells after stimulation of PBMCs with bacterial reagents with or without synthetic CRP. b Perforin expression by the bacterial component-
stimulated CD56+ NK cells. The intracellular perforin staining of CD56+ NK cells after OK432, CpG-ODN, or LPS stimulated PBMCs were cultured
with or without CRP for 24 h. PBMCs were obtained from healthy adult volunteers. MFI: mean ﬂuorescence intensity. The data are presented are the
means ± SE from six independent experiments.
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CRP protected normal mice but not FcγRII-deﬁcient
mice from LPS-induced mortality [22]. Although most
NK cells express CD16 (FcγRIII) but not CD32, CRP
reportedly binds to NK cells and is involved in NK cell
activity [24], suggesting that there is a still unknown
receptor for CRP that may be present on NK cells. In
addition, NK cells have both inhibitory (NKG2A) and
stimulatory receptors (NKG2D, NKp30, p44, p46, etc.),
and it is possible that CRP may activate NK cells by
changing the balance of these receptors. Regardless of
the mechanism, since CRP increases NK cell function
despite the decreased IL-12 production from macro-
phages stimulated with bacterial reagents, it appears
that CRP may bind to NK cells and directly affect their
function under inﬂammatory conditions. These ﬁndings
imply that the CRP co-administration with biological
response modiﬁers (such as Streptococcus and CpG-
ODN) to human cancers, may improve the antitumor
effect of these reagents with reducing side effect
induced by TNF.
Synthetic CRP modestly suppressed the production
of IL-6 and IL-10 from PBMCs or adherent macro-
phages stimulated with bacterial reagents in vitro. IL-6
and IL-10 were mainly released from macrophages in
response to tissue injury or inﬂammation [25], and IL-6
is the chief stimulator of the production of acute phase
proteins including CRP [26]. IL-10 is a representative
anti-proinﬂammatory cytokine and is important for the
resolution of inﬂammation, although it sometimes
aggravates bacterial infection [27]. Therefore, IL-6 and
IL-10 may be important cytokines for maintaining the
immune balance of hosts during infections. These results
suggest that CRP modulates the cytokine milieu in order
to not strongly suppress these cytokines.
CRP also greatly inhibited HMGB1 secretion from
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Fig. 5. The effect of synthetic CRP on cytokine production from PBMCs (a) and adherent macrophages (b) in the in vitro Shwartzman reaction.
PBMCs or adherent monocytes/macrophages were cultured with IL-12 (p40 and p70) with or without CRP for 24 h. Subsequently, cells were
further cultured with LPS for additional 24 h. The culture supernatants were collected at the indicated time points and were subjected to an ELISA
for TNF, IL-12 (p40&p70) and IFN-γ. The data are presented as the means ± SE from six independent experiments. **p<0.01, *p<0.05 vs CRP
(+) group by two-way ANOVA.
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of septic shock and lethality induced by either LPS or
CpG-DNA [17, 18]. Inside the cells, HMGB1 is present
in the nucleus as well as the cytosol and binds to CpG-
ODN provided by TLR9 [18]. When present outside of
cells, HMGB1 acts as a strong inﬂammatory cytokine-
like molecule [16]. Although TNF and IL-1 were
considered to be the main effectors in septic shock
[13], it is now clear that HMGB1 is an important late
mediator of septic shock and the resultant MODS, and
proinﬂammatory cytokines may be upstream regulators
of HMGB1.
The Shwartzman reaction is an exaggerated form of
endotoxin shock, in which lethal shock and MODS are
steadily evoked in mice when they are injected with IL-
12 and a sublethal dose of LPS 16 h apart [13]. IFN-γ
production from NK/NKT cells during the IL-12 priming
phase, and TNF production from macrophages/Kupffer
cells after LPS stimulation are crucial for this phenom-
enon [14]. Shwartzman reaction-like phenomenon can
be reproduced in human PBMCs in vitro when they are
cultured with IL-12 for 24 h and subsequently cultured
with LPS for additional 24 h, in which a much larger
amount of TNF is produced from macrophages than
that produced from macrophages stimulated with LPS
alone (in vitro Shwartzman reaction) [6], which is
conﬁrmed in this study and synthetic CRP decreased
this phenomenon.
We have recently demonstrated in mice that the
Kupffer cells in the liver are subdivided into two subsets,
one is cytokine (IL-12 and TNF)-producing CD11b+
Kupffer cells and the other is CD68+ phagocytic Kupffer
cells [28]. The CD68+ Kupffer cells with phagocytic
activity predominate in the liver, but most of the
macrophages in the spleen and blood are weakly
phagocytic CD11b+ cells [28]. Consistently, CRP did
not signiﬁcantly increase the phagocytic activity of
human blood monocytes stimulated with LPS in vitro
(less than 10 % of monocytes phagocytose microbeads,
unpublished observation). We speculated that, in
contrast to Kupffer cells, blood monocytes essentially
have weak phagocytic activity after LPS stimulation and
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mean±SE ** p<0.01, * p<0.05 vs other groups
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Fig. 6. HMGB1 production from PBMCs (a) and adherent macrophages (b) after bacterial stimulation and the in vitro Shwartzman reaction. PBMCs
or adherent macrophages were cultured with the indicated bacterial reagents with or without CRP for 48 h. The culture supernatants were collected at
the indicated time points and were subjected to an ELISA for HMGB1. PBMCs or adherent macrophages were also similarly induced in vitro
Shwartzman-like response to that described in Fig. 5 to measure HMGB1 production. The data are presented are the means ± SE from six independent
experiments. **p<0.01, *p<0.05 vs CRP (+) group by two-way ANOVA.
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Notably, CRP augmented the cytotoxicity of NK
cells against tumor cell lines, which may be explained
by increased perforin expression of CD56+ NK cells
after stimulation with bacterial components and CRP.
CRP alone did not induce cytokine production, increase
the cytotoxicity of NK cells, nor increase the number of
NK cells in PBMCs (our unpublished observations),
suggesting that CRP may exert its effects only in the
presence of a bacterial infection or inﬂammation.
Our present in vitro results using human PBMCs also
showed that CRP overall inhibits the excessive inﬂamma-
tory immune response without reducing cellular immunity
or the T helper 1 immune response (IFN-γ). CRP also
activates complement system and binds to Fc receptor of
phagocytes, thereby increasing the opsonization of
microbes [23]. In addition, synthetic CRP treatment
increased endogenous CRP production in mice with
bacterial infection [5]. Furthermore, CRP (human or
rabbit)-transgenic mice are resistant to LPS challenge,
and not only to S. pneumoniae infection but also to gram
negative bacterial infection (Salmonella enterica serovar
Typhimurium) [29–31]. Since severe bacterial infections or
septic shock in humans are usually induce high serum CRP
levels but often accompanied by the hepatocyte injury
(which produce CRP), synthetic CRP treatment may
additionally cover the effect of endogenous CRP.
It is noteworthy that synthetic CRP peptide de-
creased the TNF production in mice with lethal
endotoxin shock or the Shwartzman reaction, but did
not reduce the TNF production in mice with lethal E.
coli infection, although CRP treatment improved the
mortality in all of these mice [5]. These ﬁndings suggest
that CRP did not decrease TNF production from macro-
phages when it was required for mice to survive a severe
bacterial infection, suggesting that CRP speciﬁcally,
delicately and appropriately regulates the innate immu-
nity depending on the circumstances.
Many cancers arise from the sites of infection,
chronic irritation and inﬂammation [32]. In addition,
several investigators have suggested that elevation of
circulating CRP levels may be related to the cancer risk
and/or prognoses [33, 34]. This may also be the case for
ischemic heart disease and ischemic cerebrovascular
disease. Nevertheless, a recent study demonstrated that
high levels of CRP may not be directly involved in the
induction of ischemic heart and cerebrovascular diseases
[35]. These and current ﬁndings suggest that CRP may
reﬂect the inﬂammatory condition of the patients and
CRP itself may not be involved in the induction of
cancers and ischemic vascular diseases.
Taken together, the present ﬁndings indicate that
CRP is a strong and sophisticated modulator of innate
immune leukocytes, implying its therapeutic potential in
human septic shock.
REFERENCES
1. Volanakis, J.E. 2001. Human C-reactive protein: expression,
structure, and function. Molecular Immunology 38: 189–197.
2. Du Clos, T.W. 2000. Function of C-reactive protein. Annals of
Medicine 32: 274–278.
3. Barna, B.P., M.J. Thomassen, M. Maier, S.V. Medendorp, R.R.
Tubbs, T. Chiang, P. Zhou, B. Yen-Lieberman, S. Singh-Burgess,
and S.D. Deodhar. 1994. Combination therapy with a synthetic
peptide of C-reactive protein and interleukin 2: augmented survival
and eradication of pulmonary metastases. Cancer Immunology,
Immunotherapy 38: 38–42.
4. Zhong, W., Q. Zen, J. Tebo, K. Schlottmann, M. Coggeshall, and
R.F. Mortensen. 1998. Effect of human C-reactive protein on
chemokine and chemotactic factor-induced neutrophil chemotaxis
and signaling. Journal of Immunology 161: 2533–2540.
5. Inatsu, A., M. Kinoshita, H. Nakashima, J. Shimizu, D. Saitoh, S.
Tamai, and S. Seki. 2009. Novel mechanism of C-reactive protein
for enhancing mouse liver innate immunity. Hepatology 49: 2044–
2054.
6. Motegi, A., M. Kinoshita, K. Sato, N. Shinomiya, S. Ono, S.
Nonoyama, H. Hiraide, and S. Seki. 2006. An in vitro Shwartzman
reaction-like response is augmented age-dependently in human
peripheral blood mononuclear cells. Journal of Leukocyte Biology
79: 463–472.
7. Kawabata, T., M. Kinoshita, A. Inatsu, Y. Habu, H. Nakashima, N.
Shinomiya, and S. Seki. 2008. Functional alterations of liver innate
immunity of mice with aging in response to CpG-oligodeoxynu-
cleotide. Hepatology 48: 1586–1597.
8. Seki, S., Y. Habu, T. Kawamura, K. Takeda, H. Dobashi, T.
Ohkawa, and H. Hiraide. 2000. The liver as a crucial organ in the
ﬁrst line of host defense: the roles of Kupffer cells, natural killer
(NK) cells and NK1.1 Ag+ T cells in T helper 1 immune
responses. Immunology Reviews 174: 35–46.
9. Seki, S., H. Nakashima, andM. Kinoshita. 2012. The liver as a pivotal
innate immune organ. Immuno-Gastroenterology 1: 76–89.
10. Lopez-Verges, S., J.M. Milush, S. Pandey, V.A. York, J. Arakawa-
Hoyt, H. Pircher, P.J. Norris, D.F. Nixon, and L.L. Lanier. 2010.
CD57 deﬁnes a functionally distinct population of mature NK cells
in the human CD56dimCD16+ NK-cell subset. Blood 116: 3865–
3874.
11. Kawarabayashi, N., S. Seki, K. Hatsuse, T. Ohkawa, Y. Koike, T.
Aihara, Y. Habu, R. Nakagawa, K. Ami, H. Hiraide, and H.
Mochizuki. 2000. Decrease of CD56(+)T cells and natural killer
cells in cirrhotic livers with hepatitis C may be involved in their
susceptibility to hepatocellular carcinoma. Hepatology 32: 962–
969.
12. Seki, S., H. Nakashima, M. Nakashima, and M. Kinoshita. 2011.
Antitumor immunity produced by the liver Kupffer cells, NK cells,
NKT cells, and CD8 CD122 T cells. Clinical & Developmental
Immunology: 868345.
13. Ozmen, L., M. Pericin, J. Hakimi, R.A. Chizzonite, M. Wysocka,
G. Trinchieri, M. Gately, and G. Garotta. 1994. Interleukin 12,
interferon gamma, and tumor necrosis factor alpha are the key
cytokines of the generalized Shwartzman reaction. The Journal of
Experimental Medicine 180: 907–915.
791Suppression of Proinﬂammatory Cytokines by CRP
14. Sato, K., M. Kinoshita, A. Motegi, Y. Habu, E. Takayama, S.
Nonoyama, H. Hiraide, and S. Seki. 2005. Critical role of the liver
CD8+ CD122+ T cells in the generalized Shwartzman reaction of
mice. European Journal of Immunology 35: 593–602.
15. Shono, S., Y. Habu, M. Nakashima, A. Sato, H. Nakashima, H.
Miyazaki, M. Kinoshita, G. Tsumatori, N. Shinomiya, and S. Seki.
2011. The immunologic outcome of enhanced function of mouse
liver lymphocytes and kupffer cells by high-fat and high-
cholesterol diet. Shock 36: 484–493.
16. Kokkola, R., A. Andersson, G. Mullins, T. Ostberg, C.J. Treutiger,
B. Arnold, P. Nawroth, U. Andersson, R.A. Harris, and H.E.
Harris. 2005. RAGE is the major receptor for the proinﬂammatory
activity of HMGB1 in rodent macrophages. Scandinavian Journal
of Immunology 61: 1–9.
17. Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M.
Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L.
Borovikova, K.R. Manogue, E. Faist, E. Abraham, J. Andersson,
U. Andersson, P.E. Molina, N.N. Abumrad, A. Sama, and K.J.
Tracey. 1999. HMG-1 as a late mediator of endotoxin lethality in
mice. Science 285: 248–251.
18. Yanai, H., T. Ban, Z. Wang, M.K. Choi, T. Kawamura, H. Negishi,
M. Nakasato, Y. Lu, S. Hangai, R. Koshiba, D. Savitsky, L.
Ronfani, S. Akira, M.E. Bianchi, K. Honda, T. Tamura, T.
Kodama, and T. Taniguchi. 2009. HMGB proteins function as
universal sentinels for nucleic-acid-mediated innate immune
responses. Nature 462: 99–103.
19. Medzhitov, R., and C.A. Janeway Jr. 1997. Innate immunity: the
virtues of a nonclonal system of recognition. Cell 91: 295–298.
20. Buttenschoen, K., D.C. Buttenschoen, D. Berger, C. Vasilescu, S.
Schafheutle, B. Goeltenboth, M. Seidelmann, and H.G. Beger.
2001. Endotoxemia and acute-phase proteins in major abdominal
surgery. American Journal of Surgery 181: 36–43.
21. Tschaikowsky, K., M. Hedwig-Geissing, J. Schmidt, and G.G.
Braun. 2011. Lipopolysaccharide-binding protein for monitoring of
postoperative sepsis: complemental to C-reactive protein or
redundant? PLoS One 6: e23615.
22. Mold, C., W. Rodriguez, B. Rodic-Polic, and T.W. Du Clos. 2002.
C-reactive protein mediates protection from lipopolysaccharide
through interactions with Fc gamma R. Journal of Immunology
169: 7019–7025.
23. Bodman-Smith, K.B., R.E. Gregory, P.T. Harrison, and J.G.
Raynes. 2004. FcgammaRIIa expression with FcgammaRI results
in C-reactive protein- and IgG-mediated phagocytosis. Journal of
Leukocyte Biology 75: 1029–1035.
24. Baum, L.L., K.K. James, R.R. Glaviano, and H. Gewurz. 1983.
Possible role for C-reactive protein in the human natural killer cell
response. The Journal of Experimental Medicine 157: 301–311.
25. Tateishi, Y., S. Oda, M. Nakamura, K. Watanabe, T. Kuwaki, T.
Moriguchi, and H. Hirasawa. 2007. Depressed heart rate variability
is associated with high IL-6 blood level and decline in the blood
pressure in septic patients. Shock 28: 549–553.
26. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other
systemic responses to inﬂammation. The New England Journal of
Medicine 340: 448–454.
27. Hiraki, S., S. Ono, M. Kinoshita, H. Tsujimoto, S. Seki, and H.
Mochizuki. 2007. Interleukin-18 restores immune suppression in
patients with nonseptic surgery, but not with sepsis. American
Journal of Surgery 193: 676–680.
28. Kinoshita, M., T. Uchida, A. Sato, M. Nakashima, H. Nakashima,
S. Shono, Y. Habu, H. Miyazaki, S. Hiroi, and S. Seki. 2010.
Characterization of two F4/80-positive Kupffer cell subsets by their
function and phenotype in mice. Journal of Hepatology 53: 903–
910.
29. Szalai, A.J., D.E. Briles, and J.E. Volanakis. 1995. Human C-
reactive protein is protective against fatal Streptococcus pneumo-
niae infection in transgenic mice. Journal of Immunology 155:
2557–2563.
30. Xia, D., and D. Samols. 1997. Transgenic mice expressing rabbit
C-reactive protein are resistant to endotoxemia. Proceedings of the
National Academy of Sciences of the United States of America 94:
2575–2580.
31. Szalai, A.J., J.L. VanCott, J.R. McGhee, J.E. Volanakis, and W.H.
Benjamin Jr. 2000. Human C-reactive protein is protective against
fatal Salmonella enterica serovar typhimurium infection in trans-
genic mice. Infection and Immunity 68: 5652–5656.
32. Coussens, L.M., and Z. Werb. 2002. Inﬂammation and cancer.
Nature 420: 860–867.
33. Allin, K.H., and B.G. Nordestgaard. 2011. Elevated C-reactive
protein in the diagnosis, prognosis, and cause of cancer. Critical
Reviews in Clinical Laboratory Sciences 48: 155–170.
34. Woo, Y., W.J. Hyung, K. Obama, H.I. Kim, K.H. Pak, T. Son, and
S.H. Noh. 2012. Elevated high-sensitivity C-reactive protein, a
marker of advanced stage gastric cancer and postgastrectomy
disease recurrence. Journal of Surgical Oncology 105: 405–409.
35. Zacho, J., A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen,
and B.G. Nordestgaard. 2008. Genetically elevated C-reactive
protein and ischemic vascular disease. The New England Journal
of Medicine 359: 1897–1908.
792 Sato, Nakashima, Kinoshita, Nakashima, Ogawa, Shono, Ikarashi, and Seki
